Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from NantHealth.
This two-part activity will focus on the evolution of precision medicine through the current and future use of next-generation sequencing in patient identification, therapy selection, and ongoing management.
Instructions For This Activity & Receiving Credit
This educational activity is primarily directed toward medical oncologists who treat patients with cancer. It is designed to meet the needs of community oncologists. Additionally, fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the treatment of cancer may also participate.
William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Feinberg School of Medicine
Disclosure: No relevant financial relationships with commercial interests.
Philip C. Mack, PhD
Associate Adjunct Professor
Director of Molecular Pharmacology
UC Davis Comprehensive Cancer Center
Disclosure: Grant/Research Support: Boehringer Ingelheim and Lilly Oncology; Consultant: MolecularMD and Apton.
The following individuals have no relevant financial relationships with commercial interests:
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Feb 10, 2018
February 10, 2018
New York, NY
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
Feb 28, 2018
Feb 28, 2018
Feb 28, 2018